Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CP 99994

Drug Profile

CP 99994

Latest Information Update: 04 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Schering-Plough
  • Class
  • Mechanism of Action Neurokinin 1 antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cough
  • Discontinued Allergic rhinitis; Arrhythmias; Asthma; Nausea and vomiting; Pain; Rheumatic disorders

Most Recent Events

  • 04 Aug 2009 No development reported - Preclinical for Cough in USA (IV)
  • 21 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory Tract Disorders pharmacodynamics section
  • 06 Apr 2004 Preclinical trials in Cough in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top